A detailed history of Bryn Mawr Trust CO transactions in Cure Vac N.V. stock. As of the latest transaction made, Bryn Mawr Trust CO holds 1,682 shares of CVAC stock, worth $5,029. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,682
Holding current value
$5,029
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 25, 2024

BUY
$2.74 - $3.79 $4,608 - $6,374
1,682 New
1,682 $4,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $561M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Bryn Mawr Trust CO Portfolio

Follow Bryn Mawr Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Bryn Mawr Trust CO with notifications on news.